NCT03420469已完成早期 1 期
Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- Exposure
研究概览
简要总结
Primary objectives:
- To comprehensively characterize steady state stereoselective pharmacokinetics of bupropion and its primary and secondary metabolites in healthy volunteers
- To prospectively determine the time course (onset), extent and offset of CYP2D6 inhibition in relation to the pharmacokinetic profiles of bupropion and metabolites.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female (approximately 1:1) volunteers between the age of 18 and 55 years old and within 32% of your ideal body weight.
- •Judged healthy without any significant medical condition as determined by and decided from a pre-enrollment screening session that include medical history, laboratory tests such as blood and urine tests, and an electrical tracing of the heart beat (electrocardiogram, EKG).
- •Individuals who agree to refrain from taking any prescriptions medications, over-the-counter medications, and herbal, dietary, and alternative supplements that may interact with the metabolism of those study drugs at least 2 weeks prior to the start of the study and until study completion.
- •Nonsmoker or individuals willing to refrain from smoking or use of tobacco or marijuana for at least two weeks prior to and until the completion of the study (the entire study lasts for approximately 32 days).
- •Willing to commit the time requested for this study
排除标准
- •Subjects will be excluded from the study if they:
- •Are underweight (weigh less than 52 kg or 114 lb) or overweight [body mass index (BMI) greater than 32].
- •Have laboratory results that do not fall in a healthy range (e.g., blood hemoglobin less than 12.0 mg/dl).
- •Have baseline EKG readings that are abnormal that could place the patient at the higher risk as decided by the study medical doctor (MD)
- •Have history of intolerance, allergic reactions (e.g. rash) or other forms of hypersensitivities to any of the study medications (dextromethorphan and bupropion).
- •Have current alcohol (more than 4 alcoholic drinks per day on a regular basis) or drug abuse.
- •Have history or current gastrointestinal (digestive) disorders such as persistent diarrhea or malabsorption that would interfere with the absorption of orally administered drugs
- •Have history or current seizures, hypertension and heart disease or any other cardiovascular disorders
- •Have history or current psychiatric (mental or brain) disorders (e.g., feeling sad or unhappy, loss of interest in normal activities, worried) such as depression, anxiety, or suicidality or suicide attempts.
- •Have significantly compromised liver and/or kidney functions.
- •Have participated in a research study involving intensive blood sampling or have donated blood within the past two months
- •Are unable or unwilling to stop taking other substances that may interfere with the metabolism of the study drugs (bupropion and dextromethorphan) two weeks prior to and during the entire study period, including prescription medications, over-the-counter medications, herbal or dietary supplements, and alternative medicines.
- •Are employees or students under supervision of any of the study investigators.
- •Cannot state a good understanding of this study including risks and requirements; are unable to follow the rules of this study.
- •Cannot commit the time requested for this study.
研究组 & 干预措施
Baseline CYP2D6 activity
Experimental
CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug at baseline (control).
干预措施: Bupropion (Drug)
CYP2D6 activity with single dose of bupropion
Experimental
The effect of a single dose of bupropion (150 mg PO) on CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug.
干预措施: Bupropion (Drug)
CYP2D6 activity after treatment with bupropion to steady sate
Experimental
CYP2D6 activity will be determined using a single oral dose of dextromethorphan (30 mg PO) as a probe drug after 14 days pretreatment with bupropion (150 mg twice daily PO).
干预措施: Bupropion (Drug)
结局指标
主要结局
Exposure
时间窗: Through study completion, an average of 2 year
Area under the plasma concentration versus time curves (AUC0-inf) of bupropion and its metabolites as well as CYP2D6 activity measured by dextromethorphan to dextrorphan
次要结局
未报告次要终点
研究者
Zeruesenay Desta
Professor of Medicine, Pharmacology and Toxicology
Indiana University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pharmacogenetics of Bupropion MetabolismMetabolismPharmacokineticsNCT00791869University of California, San Francisco43
进行中（未招募）
1 期
Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study)EUCTR2008-001302-16-DEMedical Faculty, Otto-von-Guericke University
进行中（未招募）
1 期
Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an omeprazole therapy in patients with GERD -- a pilot study (phase IV-study)The presented study has to evaluate whether an optimized individual dosage of proton pump inhibitors, adjusted to CYP2C19 genotype, leads to a better pharmakodynamic effect (pH metric acid suppression). This question shall be examined within a duration of 14 days of therapy.EUCTR2006-002346-11-DEMedical Faculty, Otto-von-Guericke University
已完成
4 期
Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release PatternsDepressionNCT02078180University of Michigan34
终止
1 期
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting ConditionsDepressive DisorderNCT01046214Teva Pharmaceuticals USA8